NSABP Foundation

Recent papers from NSABP Foundation

1. Treatment-related neutropenia as predictor of response to adjuvant palbociclib in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)JNCI Journal of the National Cancer Institute · 2026
2. Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trialNature Medicine · 2026
3. Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without AtezolizumabJCO Precision Oncology · 2026
4. Epigenome-wide DNA methylation and genome-wide genotyping in participants entered on NSABP P-1 and P-2 breast cancer prevention trialsBreast Cancer Research · 2026
5. An Artificial Intelligence (AI) model integrating multiscale foundation model histopathology representations with molecular and clinical features predicts early and late distant recurrence in TAILORxnpj Breast Cancer · 2026
6. Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trialAnnals of Oncology · 2026
7. COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal CancerJournal of Clinical Oncology · 2026
8. Development and Validation of a Multimodal-Multitask Deep Learning Approach for Estimating Late Distant Recurrence Risk in HR–Positive Early Breast CancerCancer Research Communications · 2026
9. Lumpectomy Margins and Local Recurrence in DCISJAMA Surgery · 2026
10. EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual diseaseFuture Oncology · 2026
11. NSABP FC-13 (EMPIRE): A phase II platform study of cemiplimab monotherapy or cemiplimab-based combinations in patients with colorectal cancer and minimal residual disease (MRD) after definitive therapy.Journal of Clinical Oncology · 2026
12. A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2– breast cancer and Oncotype recurrence score ≤ 25 (OFSET): NRG-BR009.Journal of Clinical Oncology · 2026
13. NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA).Journal of Clinical Oncology · 2026
14. AI-driven risk stratification for distant recurrence in node-positive HR+/HER2− early breast cancer: Independent validation in the NSABP B-28 trial.Journal of Clinical Oncology · 2026
15. AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41npj Breast Cancer · 2026
16. Abstract CT013: Whole-exome sequencing tumor-informed circulating tumor DNA detection after completion of neoadjuvant treatment predicts non-pCR and distant recurrence in patients with early triple-negative breast cancer (TNBC) — Results from a sub-study of the NSABP B-59/GBG-96-GeparDouze TrialCancer Research · 2026
17. Use of ctDNA in Older Women with ER+ Breast Cancer to Facilitate Surgical De-escalation: A Prospective, Hybrid-Decentralized Trial with Correlative StudiesClinical Cancer Research · 2026
18. Clinical and histopathological characterization of metastatic lobular breast cancer: lessons learned from post-mortem tissue donation programsnpj Breast Cancer · 2026
19. Abstract PS3-04-08: Independent Validation of a Pathology-Based Multimodal Artificial Intelligence Biomarker for Predicting Risk of Distant Metastasis in Postmenopausal, Estrogen Receptor-Positive, Early-Stage Breast Cancer Patients: Analysis of the ABCSG Trial 8Clinical Cancer Research · 2026
20. Abstract RF7-07: Adjuvant Palbociclib for ER+ Breast Cancer in the PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): Post-Recurrence Treatment and Overall SurvivalClinical Cancer Research · 2026